Thesis
Ichor builds the fluid-delivery subsystems that sit inside semiconductor manufacturing equipment, moving specialty gases and chemicals through etch, deposition, cleaning, and related process tools with the purity and control advanced fabs require. That sounds like support hardware until you remember how modern semiconductor tools work: a lot of the yield risk is in getting very reactive chemistries to the chamber in exactly the right way, at exactly the right pressure and flow, without introducing contamination or variability. Ichor sells directly into that problem.
The business is in a more interesting place than the stock usually gets credit for. In 2025, revenue rose 11.6% to $947.7 million, and management entered 2026 talking about a strengthening demand environment with first-quarter 2026 revenue guided to $240 million to $260 million. The catch is that Ichor still looks messy on profitability. Full-year GAAP gross margin was only 9.3%, and even non-GAAP operating margin was just 2.2%. So the real investment question is not whether semiconductor demand is improving. It is whether Ichor can convert a healthier equipment cycle plus a broader proprietary portfolio into meaningful margin repair. If it can, the stock has much more earnings leverage than people anchored to the trough assume. If it cannot, it stays a levered subsystem name with chronic concentration and mediocre returns.
Ichor clearly benefits from a healthier semiconductor-equipment environment. The real question is whether that stronger demand finally translates into durable margin repair and a better quality business, not just higher trough-to-peak revenue.
Valuation and financials
The 4Ps
Phil Barros and the current team do not need to prove that Ichor has relevant products. They need to prove they can run the business better. The 2025 results showed healthy demand, but margins were still burdened by restructuring, inventory impairment, and operating inefficiencies. This is an execution story before it is a narrative story.
Ichor's core products are gas and chemical delivery subsystems, plus the machining, weldments, valves, control content, and related components that help semiconductor tools handle aggressive chemistries precisely. These systems are not glamorous, but they are process-critical. If the chemistry is not delivered correctly, the wafer yield suffers regardless of how good the rest of the tool is.
The stock does not require a heroic semiconductor boom to work. It requires healthier demand plus better factory economics. Because margins are still depressed, a cleaner operating model can drive earnings leverage faster than revenue alone would suggest. That is why the setup can look interesting after a difficult margin period.
Ichor has deep, long-standing relationships with major OEMs and often engages early in product development, which helps it stay relevant through tool ramps. But the revenue base is highly concentrated, and that makes quarterly visibility more fragile than it first appears. When Lam and Applied are spending, the setup looks clear. When they pause, the whole story moves quickly.
Portfolio manager lens
Starting point: Ichor is a levered way to own a healthier etch and deposition environment, but the real upside comes from fixing margins, not simply shipping more subsystems.
What is in the stock: improving customer demand, a sequential revenue step-up into early 2026, and some expectation that 2025's ugly margin profile was closer to a trough than a new normal.
What can still surprise upside: stronger gross-margin repair, more proof that proprietary content is scaling, and a broader semiconductor recovery that keeps Lam and Applied spending healthy.
What changes the view: another margin stall, customer concentration biting harder than expected, or a recovery in revenue that still fails to produce meaningful earnings leverage.
Trade framing
This is still early in the margin-repair story. The market sees the healthier demand environment, but it has not yet granted Ichor much confidence that the business is becoming structurally better. That means the best setup is around proof points, not abstract story-telling.
The next practical checkpoints are clear: does first-quarter 2026 revenue land in or above the $240 million to $260 million range, do non-GAAP gross and operating margins move up from fourth-quarter levels, and does management keep describing 2026 as a year of strong earnings leverage rather than just stronger shipments? If those answers stay positive, the stock has more upside than a typical subsystem recovery. If they do not, it will slide back into the box the market usually assigns it.
What matters now
What matters now is whether stronger wafer-fab-equipment demand finally translates into durable margin repair for Ichor. The checkpoints are subsystem demand at key OEM customers, service and content mix, and whether earnings quality improves enough to shrink the long-standing discount.
Key questions
Ichor designs, engineers, and manufactures gas delivery and chemical delivery subsystems used in semiconductor capital equipment. Gas delivery systems control the specialty gases used in processes like etch and deposition, while chemical delivery systems blend and dispense reactive liquid chemistries used in CMP, electroplating, and cleaning. The company also makes the precision-machined parts, weldments, specialty joining, surface treatments, and proprietary components that support those subsystems.
The easiest way to think about it is that Ichor sits between the semiconductor OEM and the wafer-processing chamber. The OEM still sells the full tool, but Ichor often builds the fluid-delivery layer that gets the process chemistry where it needs to go with the necessary speed, repeatability, and cleanliness.
Thesis last reviewed April 2, 2026. Live data updates automatically.